Cart
sales@molnova.com
4-Hydroxy-3-nitrophenylacetic acid
CAS No. 10463-20-4
4-Hydroxy-3-nitrophenylacetic acid( —— )
Catalog No. M10226 CAS No. 10463-20-4
It is a small molecular drug, active to Ig heavy chain V-I region and Ig gamma-2 chain C region.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 50MG | 43 | In Stock |
|
| 100MG | 56 | In Stock |
|
| 200MG | 79 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name4-Hydroxy-3-nitrophenylacetic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionIt is a small molecular drug, active to Ig heavy chain V-I region and Ig gamma-2 chain C region.
-
DescriptionIt is a small molecular drug, active to Ig heavy chain V-I region and Ig gamma-2 chain C region.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorIg gamma-2 chain C region| Ig heavy chain V-I region
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number10463-20-4
-
Formula Weight197.14
-
Molecular FormulaC8H7NO5
-
Purity>98% (HPLC)
-
SolubilityLimited solubility
-
SMILESOC(=O)CC1=CC(=C(O)C=C1)[N+]([O-])=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Berman HM, et al. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
molnova catalog
related products
-
5-HT2B antagonist-1
5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 of 33.4 nM, suitable for studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease, or gastrointestinal disease .
-
Raddeanoside 20
Raddeanoside 20 can slightly suppress the superoxide generation induced by N-formyl-methionyl-leucyl-phenylalanine (fMLP) in a concentration dependent manner.
-
Euchestraflavanone A
Euchrestaflavanone A is a flavonoid found in the root bark of Cudrania tricuspidate. Euchrestaflavanone A inhibits platelet aggregation and has some antiplatelet and antithrombotic properties, making it a potential compound for thromboprophylaxis.
